Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin1

Neoplasia

Volumn 13, Issue 7, 2011, Pages 643-652

  Laulajainen, Minja ^a   Muranen, Taru ^a   Nyman, Tuula A ^b   Carpén, Olli ^a,c   Grönholm, Mikaela ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DDB1 AND CUL4 ASSOCIATED FACTOR 1; MERLIN; PROTEIN KINASE B; SERINE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN COS7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; GENE; NEUROFIBROMATOSIS 2 GENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

EID: 79960052836     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11356     Document Type: Article

References (45)

1. McClatchey AI and Giovannini M (2005). Membrane organization and tumorigenesis-the NF2 tumor suppressor, merlin. Genes Dev 19, 2265-2277.
2. McClatchey AI and Fehon RG (2009). Merlin and the ERM proteins- regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol 19, 198-206.
3. Sherman L, XuHM, Geist RT, Saporito-Irwin S, Howells N, Ponta H, Herrlich P, and Gutmann DH (1997). Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15, 2505-2509.
4. Gutmann DH, Haipek CA, and Hoang Lu K (1999). Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations. J Neurosci Res 58, 706-716.
5. Grönholm M, Sainio M, Zhao F, Heiska L, Vaheri A, and Carpén O (1999). Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J Cell Sci 112, 895-904.
6. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan JP, Gupta V, Ratner N, Der CJ, et al. (2001). The Nf2 tumor suppressor, merlin, functions in rac-dependent signaling. Dev Cell 1, 63-72.
7. Kissil JL, Johnson KC, Eckman MS, and Jacks T (2002). Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 277, 10394-10399.
8. Xiao GH, Beeser A, Chernoff J, and Testa JR (2002). p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 277, 883-886.
9. Alfthan K, Heiska L, Grönholm M, Renkema GH, and Carpén O (2004). Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem 279, 18559-18566.
10. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, and Herrlich P (2001). The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15, 968-980.
11. Jin H, Sperka T, Herrlich P, andMorrison H (2006). Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 442, 576-579.
12. Laulajainen M, Muranen T, Carpén O, and Grönholm M (2008). Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton. Oncogene 27, 3233-3243.
13. Vivanco I and Sawyers CL (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489-501.
14. Franke TF (2008). PI3K/Akt: getting it right matters. Oncogene 27, 6473-6488.
15. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, and Cohen P (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Ba. Curr Biol 7, 261-269.
16. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, and Hemmings BA (1996). Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15, 6541-6551.
17. Li Y, Tennekoon GI, Birnbaum M, Marchionni MA, and Rutkowski JL (2001). Neuregulin signaling through a PI3K/Akt/Bad pathway in Schwann cell survival. Mol Cell Neurosci 17, 761-767.
18. Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D, and Hung G (2003). Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 23, 1493-1500.
19. Rong R, Tang X, Gutmann DH, and Ye K (2004). Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci USA 101, 18200-18205.
20. Jacob A, Lee TX, Neff BA, Miller S, Welling B, and Chang LS (2008). Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma. Otol Neurotol 29, 58-68.
21. Ammoun S, Flaiz C, Ristic N, Schuldt J, and Hanemann CO (2008). Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 68, 5236-5245.
22. Hilton DA, Ristic N, and Hanemann CO (2009). Activation of ERK, AKTand JNK signalling pathways in human schwannomas in situ. Histopathology 55, 744-749.
23. Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, and Testa JR (2005). A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65, 8090-8095.
24. Tang X, Jang SW, Wang X, Liu Z, Bahr SM, Sun SY, Brat D, Gutmann DH, and Ye K (2007). Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol 9, 1199-1207.
25. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, et al. (2010).Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140, 477-490.
26. den Bakker MA, Tascilar M, Riegman PH, Hekman AC, Boersma W, Janssen PJ, de Jong TA, Hendriks W, van der Kwast TH, and Zwarthoff EC (1995). Neurofibromatosis type 2 protein co-localizes with elements of the cytoskeleton. Am J Pathol 147, 1339-1349.
27. O'Connell KL and Stults JT (1997). Identification of mouse liver proteins on two-dimensional electrophoresis gels by matrix-assisted laser desorption/ionization mass spectrometry of in situ enzymatic digests. Electrophoresis 18, 349-359.
28. Shevchenko A, Wilm M, Vorm O, and Mann M (1996). Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68, 850-858.
29. Nyman TA, Rosengren A, Syyrakki S, Pellinen TP, Rautajoki K, and Lahesmaa R (2001). A proteome database of human primary T helper cells. Electrophoresis 22, 4375-4382.
30. Ohman T, Lietzen N, Valimaki E, Melchjorsen J, Matikainen S, and Nyman TA (2010). Cytosolic RNA recognition pathway activates 14-3-3 protein mediated signaling and caspase-dependent disruption of cytokeratin network in human keratinocytes. J Proteome Res 9, 1549-1564.
31. Brazil DP, Park J, and Hemmings BA (2002). PKB binding proteins. Getting in on the akt. Cell 111, 293-303.
32. Okada M, Wang Y, Jang SW, Tang X, Neri LM, and Ye K (2009). Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res 69, 4043-4051.
33. Huang J and Chen J (2008). VprBP targets merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation. Oncogene 27, 4056-4064.
34. Cole BK, Curto M, Chan AW, and McClatchey AI (2008). Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol 28, 1274-1284.
35. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, and Cohen P (1996). Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 399, 333-338.
36. Basu S, Totty NF, Irwin MS, Sudol M, and Downward J (2003). Akt phosphorylates the yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11, 11-23.
37. Chen Q, Powell DW, Rane MJ, Singh S, Butt W, Klein JB, and McLeish KR (2003). Akt phosphorylates p47phox and mediates respiratory burst activity in human neutrophils. J Immunol 170, 5302-5308.
38. Jones GN, Tep C, Towns WH II, Mihai G, Tonks ID, Kay GF, Schmalbrock PM, Stemmer-Rachamimov AO, Yoon SO, and Kirschner LS (2008). Tissuespecific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production. Neoplasia 10, 1213-1221.
39. Brault E, Gautreau A, Lamarine M, Callebaut I, Thomas G, and Goutebroze L (2001). Normal membrane localization and actin association of the NF2 tumor suppressor protein are dependent on folding of its N-terminal domain. J Cell Sci 114, 1901-1912.
40. Shimizu T, Seto A, Maita N, Hamada K, Tsukita S, Tsukita S, and Hakoshima T (2002). Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J Biol Chem 277, 10332-10336.
41. Bianchi AB, Hara T, Ramesh V, Gao J, Klein-Szanto AJ, Morin F, Menon AG, Trofatter JA, Gusella JF, and Seizinger BR (1994). Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 6, 185-192.
42. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, and Minna JD (1995). Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55, 1227-1231.
43. Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, and Yu Q (2008). Merlin is a potent inhibitor of glioma growth. Cancer Res 68, 5733-5742.
44. Lassman AB (2004). Molecular biology of gliomas. Curr Neurol Neurosci Rep 4, 228-233.
45. Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen CS, Giovannini M, Jacob A, Welling DB, and Chang LS (2009). Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer 45, 1709-1720.